Inhaled insulin for controlling blood glucose in patients with diabetes

References

• AhmedIGoldsteinBJCardiovascular risk in the spectrum of type 2 diabetes mellitusMt Sinai J Med2006737596817008936
   PubMedGoogle Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2007Diabetes Care200730Suppl 1S4S4117192377
   PubMedGoogle Scholar
• BarnettAHDreyerMLangePAn open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metforminDiabetes Care2006a2918182516873786
   PubMed Web of Science ®Google Scholar
• BarnettAHDreyerMLangePAn open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylureaDiabetes Care2006b291282716732009
   PubMed Web of Science ®Google Scholar
• BarnettAHfor the Exubera Phase III Study GroupEfficacy and one-year pulmonary safety of inhaled insulin (Exubera®) as adjunctive therapy with metformin or glibenclamide in Type 2 diabetes patients poorly controlled on oral agent monotherapyDiabetes200453Suppl 2A107
   Google Scholar
• BeckerRHShaSFrickADThe effect of smoking cessation and subsequent resumption on absorption of inhaled insulinDiabetes Care2006292778216443873
   PubMed Web of Science ®Google Scholar
• BlondeLRosenstockJTriplittCWhat are incretins, and how will they influence the management of type 2 diabetesJ Manag Care Pharm200612212
   PubMed Web of Science ®Google Scholar
• BonoraECorraoGBagnardiVPrevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitusDiabetologia2006498465416532323
   PubMed Web of Science ®Google Scholar
• BrownJBNicholsGAPerryAThe burden of treatment failure in type 2 diabetesDiabetes Care20042715354015220224
   PubMed Web of Science ®Google Scholar
• BrownleeMThe pathobiology of diabetic complications: a unifying mechanismDiabetes20055416152515919781
   PubMed Web of Science ®Google Scholar
• BuseJBKlonoffDCNielsenLLMetabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trialsClin Ther2007291395317379054
   PubMed Web of Science ®Google Scholar
• CefaluWRosenstockJKliozeSSustained efficacy and tolerability of inhaled human insulin (Exubera®). Therapy over 2 years: patients with type 2 diabetesDiabetologia200649Suppl 13 Abstract 1004
   Google Scholar
• CefaluWTPoint: pulmonary inhalation of insulin: another “brick in the wall”Diabetes Care2007304394117259527
   PubMed Web of Science ®Google Scholar
• CefaluWTSerdarevic-PeharMfor the Exubera Phase 3 Study GroupLong-term use of Exubera in type 2 diabetes: observations on glycemic control, pulmonary function and antibody formation [abstract]Proceedings of the American Diabetes Association 65th Annual Meeting200565 Abstract 356-OR
   Google Scholar
• CegliaLLauJPittasGMeta-Analysis: Efficacy and safety of inhaled insulin therapy in adults with diabetes mellitusAnn Intern Med20061456657517088580
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionNational Diabetes Fact Sheet: General Information and National Estimate on Diabetes in the United States [online]2005 URL: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf
   Google Scholar
• CerielloAKumarSPiconiLSimultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetesDiabetes Care2007306495417327335
   PubMed Web of Science ®Google Scholar
• DeFronzoRABergenstalRMCefaluWTEfficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trialDiabetes Care2005281922816043733
   PubMed Web of Science ®Google Scholar
• DeLongMWrightJDawsonMDose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow ratesJ Aerosol Med200518452916379620
   PubMedGoogle Scholar
• Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research GroupN Engl J Med1993329977868366922
   PubMed Web of Science ®Google Scholar
• Diabetes Medical Guidelines Task ForceThe American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management – 2002 UpdateEndocr Pract20028Suppl 1408211939758
   PubMedGoogle Scholar
• DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet2006368169670517098089
   PubMed Web of Science ®Google Scholar
• DumasREnglandRDRieseRJExubera is well tolerated and achieves tight glycemic control in patients with type 1 diabetesProceedings of the American Diabetes Association 65th Annual Meeting200565 355-OR
   Google Scholar
• EdwardsDABen-JebriaALangerRRecent advances in pulmonary drug delivery using large, porous inhaled particlesJ Appl Physiol199885379859688708
   PubMed Web of Science ®Google Scholar
• EdwardsDAHanesJCaponettiGLarge porous particles for pulmonary drug deliveryScience19972761868719188534
   PubMed Web of Science ®Google Scholar
• FDA Endocrinologic and Metabolic Drugs CommitteeSummary Minutes [online]2005 URL: http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4169M1.pdf
   Google Scholar
• FinebergSEKawabataTFinco-KentDAntibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trialJ Clin Endocrinol Metab20059032879415741258
   PubMed Web of Science ®Google Scholar
• FreemantleNBlondeLDuhotDAvailability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetesDiabetes Care200528427815677807
   PubMed Web of Science ®Google Scholar
• FreemantleNBlondeLHobbsFDThe availability of inhaled human insulin may lead to a greater acceptance of insulin therapy in European type 2 diabetes patients failing on diet and/or oral agent therapy [abstract]Diabetologia200649Suppl 13 Abstract 1010
   Google Scholar
• GargSRosenstockJSilvermanBLEfficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetesDiabetologia200649891916506054
   PubMed Web of Science ®Google Scholar
• HauberABJohnsonFRSauriolLRisking health to avoid injections: preferences of Canadians with type 2 diabetesDiabetes Care2005282243516123499
   PubMed Web of Science ®Google Scholar
• HayesRPMuchmoreDSchmitkeJEffect of inhaled insulin on patient-reported outcomes and treatment preference in patients with type 1 diabetesCurr Med Res Opin2007a234354217288697
   PubMed Web of Science ®Google Scholar
• HayesRPNakanoMMuchmoreDEffect of standard (self-directed) training versus intensive training for Lilly/Alkermes human insulin inhalation powder delivery system on patient-reported outcomes and patient evaluation of the systemDiabetes Technol Ther2007b9899817316103
   PubMed Web of Science ®Google Scholar
• HeineRJVan GaalLFJohnsDExenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med20051435596916230722
   PubMed Web of Science ®Google Scholar
• HeinemannLAlternative delivery routes: inhaled insulinDiabetes Nutr Metab2002154172212678460
   PubMedGoogle Scholar
• HeiseTBottSTusekCThe effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic studyDiabetes Care2005282161916123484
   PubMed Web of Science ®Google Scholar
• HermanGAStevensCVanDKPharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral dosesClin Pharmacol Ther2005786758816338283
   PubMed Web of Science ®Google Scholar
• HermansenKRonnemaaTPetersenAHIntensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetesDiabetes Care200427162714693983
   PubMed Web of Science ®Google Scholar
• HimmelmannAJendleJMellenAThe impact of smoking on inhaled insulinDiabetes Care2003266778212610021
   PubMed Web of Science ®Google Scholar
• HollanderPABlondeLRoweREfficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trialDiabetes Care20042723566215451900
   PubMed Web of Science ®Google Scholar
• JelesoffNEFeinglosMGrangerCBOutcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trialsCoron Artery Dis19967732438970764
   PubMed Web of Science ®Google Scholar
• KhawKTWarehamNBinghamSAssociation of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in NorfolkAnn Intern Med20041414132015381514
   PubMed Web of Science ®Google Scholar
• KingGLWakasakiHTheoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetesDiabetes Care199922Suppl 3C31C710189560
   PubMedGoogle Scholar
• KorytkowskiMWhen oral agents fail; practical barriers to starting insulinInt J Obes200226S18S24
   PubMed Web of Science ®Google Scholar
• MaloneJKKerrLFCampaigneBNCombined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapyClin Ther20042620344415823767
   PubMed Web of Science ®Google Scholar
• MaloneJKBaiSCampaigneBNTwice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetesDiabet Med2005223748115787659
   PubMed Web of Science ®Google Scholar
• MastrandreaLDQuattrinTClinical evaluation of inhaled insulinAdv Drug Deliv Rev20065810617517070613
   PubMed Web of Science ®Google Scholar
• MuchmoreDBGatesJRInhaled insulin delivery – where are we now?Diabetes Obes Metab200686344217026487
   PubMed Web of Science ®Google Scholar
• NathanDMCounterpoint: no time to inhale: arguments against inhaled insulin in 2007Diabetes Care200730442317259528
   PubMed Web of Science ®Google Scholar
• NathanDMClearyPABacklundJYIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetesN Engl J Med200535326435316371630
   PubMed Web of Science ®Google Scholar
• OwensDRGrimleyJKirkpatrickPInhaled human insulinNat Rev Drug Discov20065371216802444
   PubMed Web of Science ®Google Scholar
• PanAXde la PenaAYeoKPEffects of smoking cessation, acute re-exposure, and nicotine replacement in smokers on AIR® Inhaled Insulin pharmacokinetics and glucodynamicsBr J Clin Pharmacol2007In Press
   Web of Science ®Google Scholar
• PattonJPulmonary delivery of insulinCurr Med Res Opin200622Suppl 3511
   Google Scholar
• PeyrotMRubinRRLauritzenTResistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) studyDiabetes Care2005282673916249538
   PubMed Web of Science ®Google Scholar
• PeyrotMRubinRRSiminerioLMPhysician and nurse use of psychosocial strategies in diabetes care: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) studyDiabetes Care20062912566216732005
   PubMed Web of Science ®Google Scholar
• QuattrinTBelangerABohannonNJEfficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trialDiabetes Care2004272622715504996
   PubMed Web of Science ®Google Scholar
• RamanPKrukovetsIMarinicTEGlycosylation mediates upregulation of a potent antiangiogenic and proatherogenic protein, Thrombospondin-1, by glucose in vascular smooth muscle cellsJ Biol Chem200728257041417178709
   PubMed Web of Science ®Google Scholar
• RaskinPAllenEHollanderPInitiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogsDiabetes Care200528260515677776
   PubMed Web of Science ®Google Scholar
• RaveKde la PenaATibaldiFSAIR® inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerabilityDiabetes CareIn press
   Web of Science ®Google Scholar
• RichardsonTKerrDSkin-related complications of insulin therapy: epidemiology and emerging management strategiesAm J Clin Dermatol20034661714507228
   PubMed Web of Science ®Google Scholar
• RiddleMCThe Treat-to-Target Trial and related studiesEndocr Pract200612Suppl 171916627386
   PubMedGoogle Scholar
• RiddleMCRosenstockJGerichJThe treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsDiabetes Care2003263080614578243
   PubMed Web of Science ®Google Scholar
• RoglicGUnwinNBennettPHThe burden of mortality attributable to diabetes: realistic estimates for the year 2000Diabetes Care2005282130516123478
   PubMed Web of Science ®Google Scholar
• RosenstockJBaughmanRARivera-SchaubTA randomized, double-blind, placebo controlled study of the efficacy and safety of inhaled Technosphere® Insulin in patients with Type 2 diabetes (T2DM)Diabetes200554Suppl 1A357
   Google Scholar
• RosenstockJCappelleriJCBolinderBPatient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetesDiabetes Care20042713182315161782
   PubMed Web of Science ®Google Scholar
• RosenstockJMuchmoreDSwansonDAIR® Inhaled Insulin System: A novel insulin delivery system for patients with diabetesExpert Rev Med Devices2007aIn press
   PubMed Web of Science ®Google Scholar
• RosenstockJNakanoMSilvermanBLComparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measuresDiabetes Technol Ther2007b980817316102
   PubMed Web of Science ®Google Scholar
• RosenstockJZinmanBMurphyLJInhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trialAnn Intern Med20051435495816230721
   PubMed Web of Science ®Google Scholar
• SaltielARKahnCRInsulin signalling and the regulation of glucose and lipid metabolismNature200141479980611742412
   PubMed Web of Science ®Google Scholar
• SchaumbergDAGlynnRJJenkinsAJEffect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trialCirculation200511124465315867184
   PubMed Web of Science ®Google Scholar
• SkylerJfor the Exubera Phase 2 Study GroupSustained long-term efficacy and safety of inhaled insulin during 4 years of continuous therapyDiabetes200453Suppl 2A115
   Google Scholar
• SkylerJSCefaluWTKouridesIAEfficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept studyLancet2001357331511210993
   PubMed Web of Science ®Google Scholar
• SkylerJSJovanovicLKliozeSTwo-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with Type 1 diabetesDiabetes Care2007305798517327324
   PubMed Web of Science ®Google Scholar
• SkylerJSWeinstockRSRaskinPUse of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trialDiabetes Care2005281630515983312
   PubMed Web of Science ®Google Scholar
• SteninaOIRegulation of vascular genes by glucoseCurr Pharm Des2005a1123678116022672
   PubMed Web of Science ®Google Scholar
• SteninaOIVascular complications of diabetesCurr Pharm Des2005b112277816022667
   PubMed Web of Science ®Google Scholar
• The ACE/ADA Task Force on Inpatient DiabetesAmerican College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control: A call to actionDiabetes Care20062919556216873812
   PubMed Web of Science ®Google Scholar
• The DCCT/EDIC Research GroupRetinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research GroupN Engl J Med2000342381910666428
   PubMedGoogle Scholar
• UK Prospective Diabetes GroupUK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performanceDiabetologia199134877901778353
   PubMed Web of Science ®Google Scholar
• WatalaCBlood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitusCurr Pharm Des20051123316516022671
   PubMed Web of Science ®Google Scholar
• WeissSRChengSLKouridesIAInhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trialArch Intern Med200316322778214581245
   PubMed Web of Science ®Google Scholar
• WhiteRDOptions for insulin delivery and overcoming physician and patient concernsJ Fam Pract2006551824
   Google Scholar
• WildSRoglicGGreenAGlobal prevalence of diabetes: estimates for the year 2000 and projections for 2030Diabetes Care20042710475315111519
   PubMed Web of Science ®Google Scholar
• [WHO] World Health OrganizationDiabetes Fact Sheet [online]2006 URL: http://www.who.int/mediacentre/factsheets/fs312/en//
   Google Scholar
• Writing Team for the Diabetes Control and Complications TrialSustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) studyJAMA200329021596714570951
   PubMed Web of Science ®Google Scholar
• YachDStucklerDBrownellKDEpidemiologic and economic consequences of the global epidemics of obesity and diabetesNat Med20061262616397571
   PubMed Web of Science ®Google Scholar
• YamagishiSImaizumiTDiabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategyCurr Pharm Des20051122799916022668
   PubMed Web of Science ®Google Scholar
• ZambaniniANewsonRBMaiseyMInjection related anxiety in insulin-treated diabetesDiabetes Res Clin Pract1999462394610624790
   PubMed Web of Science ®Google Scholar